-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, JzxQy5p0WwEWPojCrfKXzDeybk58bFgHXMQWTeHDkqvxq+2eVSjzn0r3e7+RZivk 3/4j+HzHm2tW0AfV4BcCGA== 0001012870-00-002312.txt : 20000426 0001012870-00-002312.hdr.sgml : 20000426 ACCESSION NUMBER: 0001012870-00-002312 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20000425 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EXELIXIS INC CENTRAL INDEX KEY: 0000939767 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 043257395 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B3 SEC ACT: SEC FILE NUMBER: 333-96335 FILM NUMBER: 608295 BUSINESS ADDRESS: STREET 1: 260 LITTLEFIELD AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6508252200 MAIL ADDRESS: STREET 1: 260 LITTLEFIELD AVENUE CITY: SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: EXELIXIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20000106 424B3 1 PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(3) File Number 333-96335 Prospectus Supplement to Prospectus dated April 10, 2000 [LOGO OF EXELIXIS] ---------------- The purpose of this prospectus supplement is to reflect a change in the mathematical calculation of the weighted average number of shares outstanding of Exelixis' stock used to calculate the net loss per share and pro forma net loss per share, basic and diluted, for the years ended December 31, 1997, 1998 and 1999. The revised net loss per share, basic and diluted, for the years ended December 31, 1997, 1998 and 1999 were $9.97, $7.88 and $4.60, respectively, compared to amounts of $8.76, $3.83 and $3.47, respectively, previously reported on page 5, "Summary Financial Data," and page 19, "Selected Financial Data." Further, revised pro forma net loss per share, basic and diluted, for the year ended December 31, 1999 was $0.70 per share, compared to $0.67 per share as previously reported on page 5, "Summary Financial Data," and page 19, "Selected Financial Data." In addition, the change to the calculation of the weighted average number of shares outstanding affected the share and per share amounts on pages F-4, F-9, F-10, F-18, F-19, F-22 and F-37 of the financial statements. All of the information in the prospectus regarding the number of shares outstanding at the time of the initial public offering is correct. The revised net loss per share amounts also had no impact on Exelixis' previously reported revenues, net loss, cash flows or balance sheets for any period. ---------------- Prospectus Supplement dated April 25, 2000. -----END PRIVACY-ENHANCED MESSAGE-----